International Headache Society

New in Cephalalgia Reports! Headache disorders are a leading cause of disability, yet publicly funded headache clinical trials in Australia are remarkably scarce. This new paper highlights the gap and the opportunity for change. Article highlights • No funded clinical trials were identified for migraine or tension-type headache, despite their substantial burden. • A review of NHMRC and MRFF funding in Australia identified only one funded headache disorder clinical trial since 2013, focused on cluster headache. • Increased investment in headache clinical trials, workforce development, and national research infrastructure could help accelerate evidence generation and improve patient outcomes. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

📣 10 Complimentary Registrations for IHS Members! The ACEFAPERU Headache Summit 2026 will be held online on 26–28 November 2026. ACEFAPERU is offering 10 complimentary registrations to IHS members. Places are available on a first-come, first-served basis, with priority given to junior members. 📅 Application deadline: 16 November 2026 📧 To apply, email: [email protected] Learn more: ihs-headache.org/en/events/a…

New in Cephalalgia Reports! Can rheumatoid meningitis mask itself as a simple worsening of pre-existing migraine with aura? Yes, even without focal signs! Read how calculating the serum anti-CCP antibody (ACPA) index via the Reiber equation cracked this diagnostic puzzle. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

📢 Call for Papers: Jes Olesen Awards for the Advancement of Headache Medicine 🧠🏆 Submissions are now open! Cephalalgia invites researchers worldwide to submit their original research for the Jes Olesen Awards, recognising excellence and innovation in headache medicine. 🏆 Two prestigious awards: 🔬 Jes Olesen Basic Science Award 🩺 Jes Olesen Clinical Science Award Each award includes: 💶 €10,000 prize 🌍 Recognition through Cephalalgia and IHS platforms 🎤 Opportunity to present at a major scientific meeting ✅ Eligibility: • Original research papers only • First author must be under 45 years of age at submission • One submission per participant 📅 Submission deadline: 28 February 2027 📄 All submissions will undergo Cephalalgia's standard peer-review process, with winners selected from accepted papers by an expert panel. The awards are generously funded by Professor Jes Olesen through JO Health to support and inspire the next generation of headache researchers. 🔗 Submit your research: mc.manuscriptcentral.com/cep… More details: journals.sagepub.com/page/ce… Don't miss this opportunity to have your research recognised! #JesOlesenAwards #Cephalalgia #IHS #HeadacheResearch #HeadacheMedicine #CallForPapers #headache

New in Cephalalgia Reports! A letter to the editor from Uzun and Sahin responding to the recent case series by Abdalla et al. on lamotrigine in migraine with aura. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

🌍 Meet the IHC2027 Local Congress Chair, Dimos Mitsikostas, as he welcomes the global headache community to Athens: In September 2027, Athens will welcome the global headache community for IHC2027. A city renowned for its history, culture, hospitality, and spirit of discovery, Athens provides the perfect setting to connect with colleagues, exchange ideas, build collaborations, and experience the very best of the international headache community. We look forward to welcoming you to Athens and sharing an unforgettable IHC2027 together. 📍 Athens, Greece 📅 8–11 September 2027 Where science meets history. Where colleagues become friends. Where the global headache community comes together. #IHC2027 #InternationalHeadacheCongress #InternationalHeadacheSociety #Headache #Migraine #Athens

New in Cephalalgia Reports! A first-ever migraine aura was followed by a small cerebellar ischemic lesion in a patient with a patent foramen ovale, supporting a possible link between paradoxical microembolism, cortical spreading depression, and focal ischemia. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! A 69-year-old man with chronic cluster headache enjoyed a notable reduction in attack frequency with memantine 20 mg twice daily. Off-label use of memantine in cluster headache should be considered in select patients. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! In 1M+ headache-diary days, weather was a real but tiny correlate of headache reports — no reproducible "weather-sensitive" subgroup could be identified, no match to patients' own triggers, and near-chance day-level prediction. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

Meet the IHC2027 Scientific Programme Chairs: Anna Andreou and Scott Yuan! Here, they share their vision for the congress: “As Scientific Programme Chairs, we are working to develop a congress that reflects both the extraordinary progress being made across headache medicine and the challenges that still lie ahead. ‘Science that Inspires. Care that Transforms. Policy that Impacts,’ is the vision at the heart of the scientific programme for IHC2027.” Join us at the International Headache Congress! 📅 9–11 September 2027 📍 Athens, Greece #IHC2027 #HeadacheMedicine #InternationalHeadacheSociety

New in Cephalalgia Reports! The first study in the world comparing pharmacopuncture, a type of acupuncture technique, to standard oral medication (propranolol) as prophylaxis treatment for migraine. ............. GB20 pharmacopuncture with 2% lidocaine produced reductions in migraine frequency, disability and bothersome symptoms in the same direction as propranolol, without evidence of a statistically significant between-group difference. • GB20 pharmacopuncture with 2% lidocaine warrants further evaluation as a possible option for patients intolerant of or contraindicated for propranolol prophylaxis. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! This paper compared the ICHD-3 and DC/TMD diagnostic systems for headache attributed to temporomandibular disorder in the OPPERA-II cohort and found that the two approaches identify overlapping but clinically distinct headache presentations. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

Excited to share a new Call for Papers in Cephalalgia — the official journal of the International Headache Society. 🧠 Special Issue: Managing and Understanding Headache in the Context of Comorbid Conditions Guest Editors: Faraidoon Haghdoost and Henrik Winther Schytz Headache disorders such as migraine and tension-type headache rarely exist in isolation. They often sit alongside high blood pressure, dyslipidaemia, depression, anxiety, gastrointestinal disorders, and more. This special issue focuses on integrated, real-world approaches to care — from shared pathophysiology and overlapping risk factors to multidisciplinary management and treatments that address both headache and comorbid conditions. We welcome: • Original research and clinical trials • Systematic reviews and network meta-analyses • Real-world evidence • Viewpoints and perspectives If your work explores headache in the context of comorbidities — cardiovascular, mental health, gastrointestinal, or beyond — we would love to hear from you. 📅 Submission deadline: 31 December 2026 📌 Please note in your cover letter that your manuscript is for the “Headache and Comorbidities” special issue. Let’s move toward more holistic, patient-centred headache care. Looking forward to your submissions and to advancing this important conversation together. surl.lt/wadtdt #migraine #headache #brain #pain #neurology #neuroscience @faradoost @Simona_Sacco_ @HenrikSchytz

New in Cephalalgia Reports! Adjunctive masseter botox may improve outcomes in patients with chronic migraine and muscular temporomandibular disorder. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! In patients with refractory migraine, evolving systemic features may provide an important clue to an underlying neuroendocrine disorder. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! This systematic review examined EEG findings in migraine with brainstem aura. EEG was usually normal, while generalized rhythmic delta activity was the most frequently reported abnormal pattern in patients with decreased level of consciousness. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! Secondary headaches can signal serious disease. The authors reviewed warning signs (“red flags”) and organised them into a structured framework (DIPIH-T) to help clinicians decide when further testing is needed. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! Secondary headaches can signal serious disease. The authors reviewed warning signs (“red flags”) and organised them into a structured framework (DIPIH-T) to help clinicians decide when further testing is needed. ....... • Secondary headaches often present with symptoms that are uncommon in primary headaches (red flags) and should prompt further diagnostic evaluation. • Red-flag information can be organized into different domains reflecting underlying pathological processes. • The proposed DIPIH-T framework groups warning signs into neurological dysfunction, inflammation/infection, precipitating factors, intracranial pressure abnormalities, hormonal dysfunction, and temporal features. • This structured approach may help clinicians recognize potentially dangerous headaches and guide decisions about further investigations. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! Masterclass in Headache No treatment for new daily persisten headache (NDPH) has been well established. Although NDPH is rare in both general and clinic-based populations, and more frequent in adolescents than in adults, it is usually disabling and highly refractory. Link to the 'Masterclass in Headache' paper: journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia Reports! The purpose of this letter to the editor was to draw attention to the fact that Peru has two established headache organizations, rather than to explain their full activities. journals.sagepub.com/doi/epu… #migraine #headache #brain #pain #neurology #neuroscience